In episode 1 of this ongoing series, listen to a conversation between Stacey Trooskin, MD, PhD, MPH, and patient advocate Brother Dan Palmer on approaches to improve access to HCV therapy and remove barriers to care.
In episode 2 of this series, tune in to a conversation between Robert G. Gish, MD, and patient advocate Jacki Chen, PhD, about the potential benefits of simplifying our approach to treating patients with chronic hepatitis B.
Episode 4 of this series features a conversation between a patient, Jason, and Paul Y. Kwo, MD, who discuss the particular challenges that can affect people with chronic hepatitis B seeking care in rural settings.
Episode 3 of this series features a conversation between patient Melody Cheng and Anna Cristina L. dela Cruz, MD, who discuss Melody’s decision to start HBV antiviral therapy during pregnancy.
In this podcast, learn from expert faculty as they discuss key lessons from their own micro-elimination program designed to prevent HCV transmission among HIV-positive men who have sex with men.
In this podcast, CCO’s expert faculty discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV.
This episode features a conversation between a patient, Alicia, and Oluwaseun Falade-Nwulia, MBBS, MPH, who discuss how stigma in the medical system toward marginalized populations, including people who inject drugs or who have a history of injection drug use, prevents access to HCV care.
This episode features a conversation between a patient, Shelley Rossell, and Norah Terrault, MD, MPH, who discuss the importance of universal HCV screening, the ease and benefits of DAA therapy, and how patients can be effective self-advocates for, during, and after treatment
In this podcast, CCO’s expert faculty discusses how to identify which patients with chronic HBV infection may not need immediate HBV treatment and the critical need to continue monitoring such patients even in the absence of ongoing therapy.